Pharmadrug Inc.
LMLLF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $7 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $26 | $2 | $9 |
| Gross Profit | $0 | -$26 | -$2 | -$2 |
| % Margin | – | – | – | -30.7% |
| R&D Expenses | $138 | $226 | $713 | $554 |
| G&A Expenses | $113 | $751 | $1,148 | $1,158 |
| SG&A Expenses | $445 | $1,109 | $1,620 | $2,148 |
| Sales & Mktg Exp. | $333 | $358 | $471 | $990 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $583 | $1,335 | $2,332 | $2,702 |
| Operating Income | -$583 | -$1,335 | -$2,335 | -$2,704 |
| % Margin | – | – | – | -38,578.1% |
| Other Income/Exp. Net | -$290 | -$12,938 | -$919 | -$1,580 |
| Pre-Tax Income | -$873 | -$14,273 | -$3,254 | -$4,284 |
| Tax Expense | $0 | -$1,010 | -$190 | $0 |
| Net Income | -$793 | -$13,201 | -$8,876 | -$5,874 |
| % Margin | – | – | – | -83,806.5% |
| EPS | -0.008 | -0.23 | -0.061 | -0.12 |
| % Growth | 96.7% | -275.8% | 49% | – |
| EPS Diluted | -0.008 | -0.23 | -0.061 | -0.12 |
| Weighted Avg Shares Out | 99,170 | 56,415 | 50,095 | 48,344 |
| Weighted Avg Shares Out Dil | 103,930 | 56,488 | 50,095 | 47,312 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $223 | $60 |
| Depreciation & Amortization | $50 | $26 | $21 | $16 |
| EBITDA | -$583 | -$1,335 | -$2,344 | -$4,208 |
| % Margin | – | – | – | -60,037.1% |